# reload+after+2024-01-23 12:26:27.718677
address1§2117 SW Highway 484
city§Ocala
state§FL
zip§34473
country§United States
phone§352 448 7797
fax§352 480 4620
website§https://aimimmuno.com
industry§Biotechnology
industryKey§biotechnology
industryDisp§Biotechnology
sector§Healthcare
sectorKey§healthcare
sectorDisp§Healthcare
longBusinessSummary§AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
fullTimeEmployees§22
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Thomas K. Equels Esq., J.D., M.S.', 'age': 70, 'title': 'Executive Vice Chairman, CEO & President', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 1240472, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert  Dickey IV, M.B.A.', 'age': 67, 'title': 'Chief Financial Officer', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 60975, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Peter W. Rodino III, Esq., J.D.', 'age': 72, 'title': 'COO, Executive Director of Governmental Relations, General Counsel & Secretary', 'yearBorn': 1951, 'fiscalYear': 2022, 'totalPay': 630003, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ann Marie E. Coverly', 'title': 'Director of Administration & Human Resources and Deputy Investor Relations Coordinator', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Carol A. Smith', 'age': 72, 'title': 'Chief Manufacturing Officer & Deputy Chief Scientific Officer', 'yearBorn': 1951, 'fiscalYear': 2022, 'totalPay': 170767, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Christopher  McAleer Ph.D.', 'title': 'Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ralph Christopher Cavalli Ph.D.', 'age': 65, 'title': 'Vice President of QC & Manufacturing', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 234795, 'exercisedValue': 0, 'unexercisedValue': 800}, {'maxAge': 1, 'name': 'Jodie  Pelz', 'title': 'Director of Finance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§-0.028
priceToSalesTrailing12Months§111.34895
currency§USD
dateShortInterest§1702598400
forwardEps§-0.45
pegRatio§-0.04
exchange§ASE
quoteType§EQUITY
shortName§AIM ImmunoTech Inc.
longName§AIM ImmunoTech Inc.
firstTradeDateEpochUtc§837178200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§527cb9d6-69af-3507-a5c0-21ee7cf37c07
messageBoardId§finmb_97799
gmtOffSetMilliseconds§-18000000
targetHighPrice§6.0
targetLowPrice§2.0
targetMeanPrice§3.83
targetMedianPrice§3.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§3
quickRatio§4.767
grossMargins§0.84456
ebitdaMargins§0.0
trailingPegRatio§None
